Alliance Pharma PLC
31 August 2007
For Immediate Release 31 August 2007
Alliance Pharma Plc
Notification of Major Interests in Shares
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was
notified on 30 August, 2007 that RAB Special Situations (Master) Fund Ltd,
through Credit Suisse Client Nominees (UK) Ltd are now interested in 19,943,399
Ordinary Shares of Alliance Capital representing 12.31% of the issued share
capital of the Company.
-ENDS-
For further information:
Alliance Pharma plc + 44 (0) 1249466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Numis Securities + 44 (0) 20 72601000
David Poutney / Michael Meade
Buchanan Communications + 44 (0) 207466 5000
Mark Court /Rebecca Skye Dietrich
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.